33° Partly Cloudy

Site search

Open user controls
- Log In Using Your Account
  Log In
  
  Don't have an account? Sign Up Today

- My Account
- Dashboard
- Profile
- Saved items
- Logout

Home
News
- Local News
- State News
Sports
- Local Sports
- Pro Sports
Lifestyle
- Local Entertainment
Multimedia
Community Choice
Features
Classifieds
- Place Ad
- Legal Notices
Public Notices
Obituaries
E-Edition
STOCKING STUFFER CONTEST

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Zenas BioPharma, Inc. - Common Stock (NQ:ZBIO)

14.66 -1.95 (-11.74%)

Streaming Delayed Price Updated: 1:17 PM EST, Jan 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Zenas BioPharma, Inc. - Common Stock

< Previous 1 2 3 4 Next >

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zenas BioPharma, Inc. of Class Action Lawsuit and Upcoming Deadlines - ZBIO

April 21, 2025

From Pomerantz LLP

Via GlobeNewswire

Zenas BioPharma, Inc. Stockholder Notice: Robbins LLP Reminds Investors of the Class Action Lawsuit Against ZBIO

April 21, 2025

From Robbins LLP

Via GlobeNewswire

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma

April 20, 2025

From Faruqi & Faruqi LLP

Via GlobeNewswire

ROSEN, THE FIRST FILING FIRM, Encourages Zenas BioPharma, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – ZBIO

April 19, 2025

From The Rosen Law Firm PA

Via GlobeNewswire

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 17, 2025

From Zenas BioPharma

Via GlobeNewswire

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma

April 17, 2025

From Faruqi & Faruqi, LLP

Via Business Wire

ZBIO INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Zenas BioPharma, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

April 17, 2025

From Robbins Geller Rudman & Dowd LLP

Via Business Wire

ZBIO Investors Have Opportunity to Lead Zenas BioPharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm

April 16, 2025

From The Schall Law Firm

Via Business Wire

ZBIO INVESTOR NEWS: ROSEN, THE FIRST FILING FIRM, Encourages Zenas BioPharma, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – ZBIO

April 16, 2025

From The Rosen Law Firm PA

Via GlobeNewswire

EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Zenas BioPharma, Inc. – ZBIO

April 16, 2025

From The Rosen Law Firm, P.A.

Via Business Wire

Zenas BioPharma, Inc. Announcement: If You Have Suffered Losses in Zenas BioPharma, Inc. (NASDAQ: ZBIO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

April 13, 2025

From The Rosen Law Firm PA

Via GlobeNewswire

Zenas BioPharma, Inc. Investor News: If You Have Suffered Losses in Zenas BioPharma, Inc. (NASDAQ: ZBIO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

April 10, 2025

From The Rosen Law Firm PA

Via GlobeNewswire

Zenas BioPharma Appoints Haley Laken, Ph.D., as Chief Scientific Officer

April 07, 2025

Dr. Laken brings over 25 years of leadership experience in research, development operations, scientific assessment and strategy

From Zenas BioPharma

Via GlobeNewswire

Zenas BioPharma, Inc. Announcement: If You Have Suffered Losses in Zenas BioPharma, Inc. (NASDAQ: ZBIO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

April 04, 2025

From The Rosen Law Firm PA

Via GlobeNewswire

Zenas BioPharma, Inc. Announcement: If You Have Suffered Losses in Zenas BioPharma, Inc. (NASDAQ: ZBIO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

April 01, 2025

From The Rosen Law Firm PA

Via GlobeNewswire

Excelerate Energy, MediaAlpha And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

April 01, 2025

Via Benzinga

Why PVH Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket ↗

April 01, 2025

Via Benzinga

Rosen Law Firm Encourages Zenas BioPharma, Inc. Investors to Inquire About Securities Class Action Investigation – ZBIO

March 20, 2025

From The Rosen Law Firm, P.A.

Via Business Wire

Zenas BioPharma Gains Outperform Rating From Analyst As Key Autoimmune Trials Progress ↗

March 20, 2025

Wedbush initiates coverage on Zenas BioPharma, citing strong potential for obexelimab in autoimmune diseases, with key clinical data expected in 2025 and 2026.

Via Benzinga

Zenas BioPharma Appoints Lisa von Moltke, M.D., as Head of Research and Development and Chief Medical Officer

March 17, 2025

From Zenas BioPharma

Via GlobeNewswire

Zenas BioPharma Announces Key 2024 Accomplishments and 2025 Business Objectives to Support the Global Development and Commercialization of Therapies for Autoimmune Diseases

February 05, 2025

From Zenas BioPharma

Via GlobeNewswire

Zenas BioPharma to Present at the Guggenheim SMID Cap Biotech Conference

January 28, 2025

From Zenas BioPharma

Via GlobeNewswire

Progress Software, Disc Medicine And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗

January 22, 2025

Via Benzinga

This Addus HomeCare Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗

December 16, 2024

Via Benzinga

Visa To Rally Over 20%? Here Are 10 Top Analyst Forecasts For Wednesday ↗

December 11, 2024

Via Benzinga

Zenas BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

November 12, 2024

From Zenas BioPharma

Via GlobeNewswire

Zenas BioPharma Completes Targeted Enrollment of the Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD)

November 12, 2024

From Zenas BioPharma

Via GlobeNewswire

Zenas BioPharma to Participate in Upcoming Healthcare Investor Conferences

November 07, 2024

From Zenas BioPharma

Via GlobeNewswire

12 Health Care Stocks Moving In Friday's Intraday Session ↗

October 25, 2024

Via Benzinga

StandardAero Surges In Market Debut ↗

October 06, 2024

Shares of StandardAero jumped 36% in the company's trading debut as the aircraft maintenance services provider raised $1.44 billion in its IPO. Additionally, Chain Bridge Bancorp opened on Oct. 5 at...

Via Talk Markets

Topics Initial Public Offering

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sections

Home
News
Sports
Multimedia
Local Events
Classifieds
Obituaries
Weather
Online Features

Services

About Us
Contact Us
Promote Your Event
Subscriber Services
Online Forms
Rack Locations

woonsocketcall.com
Address: 154 Main Street
Woonsocket, RI 02895
Phone: 401-762-3000
Email: notices@woonsocketcall.com

Facebook
Twitter

Browser Compatibility

Your browser is out of date and potentially vulnerable to security risks.
We recommend switching to one of the following browsers:

Microsoft Edge Google Chrome Firefox

Log In Using Your Account

Zenas BioPharma, Inc. - Common Stock (NQ:ZBIO)

All News about Zenas BioPharma, Inc. - Common Stock

Sections

Services